Combination Therapy With Beta Blocker and Inotrope in Decompensated Heart Failure: A Clinical Observation
DOI:
https://doi.org/10.17140/HROJ-4-136Abstract
Inotropic support is contemplated in the presence of ongoing end-organ hypoperfusion or
refractory symptoms in decompensated heart failure (DHF). However, inotropic agents may
cause tachycardia leading to increased myocardial oxygen demand and arrhythmogenesis.1
Introduction of beta blocker (BB) therapy in DHF patients requiring inotrope support is
discouraged due to the negative hemodynamic impact of acute BB therapy.2-5 On the other
hand, reduction in heart rate by BB therapy results in decreased myocardial oxygen demand
and increased ventricular diastolic filling.6,7 Additionally, early introduction of BB therapy
improves outcome in heart failure
References
Felker GM, O’Connor CM. Inotropic therapy for heart failure: An evidence based approach. Am Heart J. 2001; 142(3): 393- 401. doi: 10.1067/mhj.2001.117606
Krum H, Sackner-Bernstein JD, Goldsmith RL, et al. Double-blind, placebo-controlled study of the long-term efficacy of carvedilol in patients with severe chronic heart failure. Circulation. 1995; 92(6): 1499-1506. doi: 10.1161/01. CIR.92.6.1499
Macdonald PS, Keogh AM, Aboyoun CL, Lund M, Amor R, McCaffrey DJ. Tolerability and efficacy of carvedilol in patients with New York Heart Association class IV heart failure. J Am Coll Cardiol. 1999; 33(4): 924-931.
Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet. 1999; 353(9169): 2001- 2007.
Cohn JN, Fowler MB, Bristow MR, et al. Safety and efficacy of carvedilol in severe heart failure. The U.S. Carvedilol Heart Failure Study Group. J Card Fail. 1997; 3(3): 173-179.
Kobayashi S, Susa T, Tanaka T, et al. Low dose beta-blocker in combination with milrinone safely improves cardiac function and eliminates pulsus alternans in patients with acute decompensated heart failure. Circ J. 2012; 76(7): 1646-1653. doi: 10.1253/circj.CJ-12-0033
Andersson B, Lomsky M, Waagstein F. The link between acute hemodynamic adrenergic beta-blockade and long-term effects in patients with heart failure: A study on diastolic function, heart rate and myocardial metabolism following intravenous metoprol. Eur Heart J. 1993; 14(10): 1375-1385. doi: 10.1093/ eurheartj/14.10.1375
Packer M, Coats AJ, Fowler MB, et al. Carvedilol prospective randomized cumulative survival study group. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med. 2001; 344(22): 1651-1658. doi: 10.1161/01.CIR.0000035653.72855. BF
Bohm M, Deutsch HJ, Hartmann D, Rosee KL, Stablein A. Improvement of postreceptor events by metoprolol treatment in patients with chronic heart failure. J Am Coll Cardiol .1997; 30(4): 992-996.
Eschenhagen T, Mende U, Nose M, et al. Increased messenger RNA level of the inhibitory G-protein a-subunits Gia2 in human end-stage heart failure. Circ Res. 1992;70:688- 696. doi: 10.1161/01.RES.70.4.688
Ungerer M, Bo¨hm M, Elce JS, Erdmann E, Lohse MJ. Altered expression of b-adrenergic receptor kinase and b1- adrenergic receptors in the failing human heart. Circulation. 1993; 87(2): 454-463. doi: 10.1161/01.CIR.87.2.454
Neumann J, Scholz H, Do¨ring V, Schmitz W, von Meyerinck L, Kalmar P. Increase in myocardial Gi-proteins in heart failure. Lancet. 1988; 2(8617): 936-937. doi: 10.1016/S0140- 6736(88)92601-3
Danielsen W, v. der Leyen H, Meyer W, et al. Basal and isoprenaline stimulated cAMP content in failing versus nonfailing human cardiac preparations. J Cardiovasc Pharmacol. 1989; 14(1): 171-173. Web site. http://journals.lww. com/cardiovascularpharm/Abstract/1989/07000/Basal_and_ Isoprenaline_Stimulated_cAMP_Content_in.26.aspx. Accessed January 2, 2017.
Lymperopoulos A, Rengo G, Koch WJ. Adrenergic system in heart failure: Pathophysiology and therapy. Circ Res. 2013; 113(6): 739-753. doi: 10.1161/CIRCRESAHA.113.300308
Capote LA, Perez RM, Lymperopoulos A. GPCR signaling and cardiac function. Eur J Pharmacol. 2015; 763: 143-148. doi: 10.1016/j.ejphar.2015.05.019
Shakar SF, Abraham WT, Gilbert EM, et al. Combined oral positive inotropic and beta-blocker therapy for treatment of refractory class IV heart failure. J Am Coll Cardiol. 1998; 31(6): 1336-1340. doi: 10.1016/S0735-1097(98)00077-1
Sigmund M, Jakob H, Becker H, et al. Effects of metoprolol on myocardial beta-adrenoceptors and Gi alpha-proteins in patients with congestive heart failure. Eur J Clin Pharmacol. 1996; 51(2): 127-132. doi: 10.1007/s002280050172
Jaiswal A, Nguyen VQ, Le Jemtel TH, Ferdinand KC. Novel role of phosphodiestarse inhibitors in the management of end-stage heart failure. Novel role of phosphodiesterase inhibitors in the management of end-stage heart failure. World J Cardiol. 2016; 8(7): 401-412. doi: 10.4330/wjc.v8.i7.401
Gilbert EM, Olsen SL, Renlund DG, Bristow MR. Beta-adrenergic receptor regulation and left ventricular function in idiopathic dilated cardiomyopathy. Am J Cardiol. 1993; 71(9): 23C-29C. doi: 10.1016/0002-9149(93)90083-O
Bristow MR. Changes in myocardial and vascular receptors in heart failure. J Am Coll Cardiol. 1993; 22(4 Suppl A): 61A-71A. doi: 10.1016/0735-1097(93)90465-D
Cutler MJ, Wan X, Laurita KR, Hajjar RJ, Rosenbaum DS. Targeted SERCA2a gene expression identifies molecular mechanism and therapeutic target for arrhythmogenic cardiac alternans. Circ Arrhythm Electrophysiol. 2009; 2(6): 686-694. doi: 10.1161/CIRCEP.109.863118
Lou Q, Janardhan A, Efimov IR. Remodeling of calcium handling in human heart failure. Adv Exp Med Biol. 2012; 740: 1145-1174. doi: 10.1007/978-94-007-2888-2_52
Marks AR. Calcium cycling proteins and heart failure: Mechanisms and therapeutics. J Clin Invest. 2013; 123(1): 46- 52. doi: 10.1172/JCI62834
Bristow MR. Treatment of chronic heart failure with β-adrenergic receptor antagonists: A convergence of receptor pharmacology and clinical cardiology. Circ Res. 2011; 109(10): 1176-1194. doi: 10.1161/CIRCRESAHA.111.245092
Györke S, Carnes C. Dysregulated sarcoplasmic reticulum calcium release: Potential pharmacological target in cardiac disease. Pharmacol Ther. 2008; 119(3): 340-354. doi: 10.1016/j. pharmthera.2008.06.002
Kobayashi S, Susa T, Ishiguchi H, et al. A low-dose β1- blocker in combination with milrinone improves intracellular Ca2+ handling in failing cardiomyocytes by inhibition of milrinone-induced diastolic Ca2+ leakage from the sarcoplasmic reticulum. PLoS ONE. 2015; 10(1): e0114314. doi: 10.1371/ journal.pone.0114314
Lader AS, Xiao YF, Ishikawa Y, et al. Cardiac Gsalpha overexpression enhances L-type calcium channels through an adenylyl cyclase independent pathway. Proc Natl Acad Sci U S A. 1998; 95(16): 9669-9674. Web site. http://www.pnas.org/ content/95/16/9669.short. Accessed January 2, 2017.
Hall JA, Ferro A, Dickerson JE, Brown MJ. Beta adrenoreceptor subtype cross regulation in the human heart. Br Heart J. 1993; 69(4): 332-337. doi: 10.1136/hrt.69.4.332
Liggett SB, Tepe NM, Lorenz JN, et al. Early and delayed consequences of beta (2)-adrenergic receptor overexpression in mouse hearts: Critical role for expression level. Circulation. 2000; 101(14): 1707-1714. doi: 10.1161/01.CIR.101.14.1707
Communal C, Singh K, Sawyer DB, Colucci WS. Opposing effects of beta (1)-and beta (2)-adrenergic receptors on cardiac myocyte apoptosis: Role of a pertussis toxin-sensitive G protein. Circulation. 1999; 100(22): 2210-2212. doi: 10.1161/01. CIR.100.22.2210
Hauptman PJ, Woods D, Pritzker MR. Novel use of a short-acting intravenous beta blocker in combination with inotropic therapy as a bridge to chronic oral beta blockade in patients with advanced heart failure. Clin Cardiol. 2002; 25(5): 247-249. doi: 10.1002/clc.4950250512
Metra M, Nodari S, D’Aloia A, et al. Beta-blocker therapy influences the hemodynamic response to inotropic agents in patients with heart failure: A randomized comparison of dobutamine and enoximone before and after chronic treatment with metoprolol or carvedilol. J Am Coll Cardiol. 2002; 40(7): 1248-1258. doi: 10.1016/S0735-1097(02)02134-4
Colucci WS, Wright RF, Jaski BE, Fifer MA, Braunwald E. Milrinone and dobutamine in severe heart failure: Differing hemodynamic effects and individual patient responsiveness. Circulation. 1986; 73: III175-III183. Web site. http://europepmc. org/abstract/med/3510774. Accessed January 2, 2017.
Lowes BD, Higginbotham M, Petrovich L, et al. Low-dose enoximone improves exercise capacity in chronic heart failure. Enoximone Study Group. J Am Coll Cardiol. 2000; 36(2): 501- 508. Web site. http://www.pubfacts.com/detail/10933364/Low-dose-enoximone-improves-exercise-capacity-in-chronic-heart-failure-Enoximone-Study-Group. Accessed January 2, 2017.
Dage RC, Okerholm RA. Pharmacology and pharmaco-kinetics of enoximone. Cardiology. 1990; 77(Suppl 3): 27-33. doi: 10.1159/000174664
Shakar SF, Bristow MR. Low-level inotropic stimulation with type III phosphodiesterase inhibitors in patients with advanced symptomatic chronic heart failure receiving beta-blocking agents. Curr Cardiol Rep. 2001; 3(3): 224-231. doi: 10.1007/s11886-001-0027-8
Bristow MR, Shakar SF, Linseman JV, Lowes BD. Inotropes and beta-blockers: Is there a need for new guidelines? J Card Fail. 2001; 7(2 Suppl 1): 8-12.
Gattis WA, O’Conner CM, Leimberger JD, Felker GM, Adams KF, Gheorghiade M. Clinical outcomes in patients on beta-blocker therapy admitted with worsening heart failure. Am J Cardiol. 2003; 91(2): 169-174. doi: 10.1016/S0002- 9149(02)03104-1
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
All content published in Heart Research (HROJ) is licensed under the Creative Commons Attribution 4.0 International License (CC BY 4.0). This license allows anyone to copy, distribute, transmit, and adapt the work — including for commercial purposes — provided appropriate credit is given to the original author(s) and source.